mutex Raises ¥281.6M Series A for Medical Billing AI Reze

mutex, a University of Tokyo-founded startup, has raised a ¥281.6 million Series A round. The company's AI SaaS product, Reze, supports medical billing (rezept) operations at Japanese medical institutions and is working toward fully automating medical claims processing.

What mutex Does

mutex builds AI SaaS for the Japanese healthcare sector. Its product, Reze, is designed to support medical billing and rezept operations at medical institutions. The company's stated goal is to move toward fully automating medical claims processing, a complex and administratively heavy function in the Japanese medical system.

Founded out of the University of Tokyo, mutex is targeting a segment where operational efficiency and accuracy in claims processing are critical for medical institutions.

The Round

Round type: Series A
Amount: ¥281,600,000
Currency: JPY
Date: September 30, 2026

Investors

The Series A included participation from:

MTI Ltd. (株式会社エムティーアイ)
MEDIPAL Innovation Investment Limited Partnership (MEDIPAL Innovation 投資事業有限責任組合)
Nihon Keiei (株式会社日本経営)

No single lead investor was designated for the round.

Prior Funding

The Series A follows a ¥60 million seed round raised in December 2025, according to the company's funding history.

Use of Funds

According to the company, the Series A proceeds will be used to expand paid hospital deployments and accelerate product development.

Why It Matters

Medical billing and claims processing in Japan involve detailed, rule-heavy workflows that are well suited to automation. mutex's Reze product targets this operational burden directly, aiming to reduce manual effort at medical institutions while improving accuracy.

The investor group reflects strategic interest from both media/technology and healthcare distribution and consulting players. MTI Ltd. is a listed Japanese technology company, MEDIPAL Innovation Investment is tied to Medipal Holdings' CVC fund, and Nihon Keiei is a healthcare consultancy. Their participation suggests alignment between mutex's product roadmap and established healthcare and technology channels in Japan.

Acquisition Context

For acquirers in healthcare IT, medical SaaS, or revenue-cycle management, mutex represents an early-stage but strategically backed asset in the Japanese medical billing automation market. The involvement of healthcare distribution and consultancy investors may provide deployment pathways into medical institutions, while the company's University of Tokyo origins and AI SaaS focus position it within Japan's growing healthtech ecosystem.

Summary

mutex raised a ¥281.6 million Series A on September 30, 2026, with participation from MTI Ltd., MEDIPAL Innovation Investment Limited Partnership, and Nihon Keiei. The University of Tokyo-founded startup develops Reze, an AI SaaS product supporting medical billing operations at Japanese medical institutions, and plans to use the funding to expand paid hospital deployments and accelerate product development. The round follows a ¥60 million seed round in December 2025.